DiaMedica raises additional $2.5M to fund drug trial

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
WebinarM&A In Focus: Tech Acquisitions and the ‘New Normal’ in 2023
- 02/08/2023
- Live, Online
- 11:00 am - 12:00 pm EST
Webinar ReplaysAssessing the impact of the U.S. Government Accountability Office recommendations’ on Export Control Compliance at universities
- 01/18/2023
- On-Demand
- 60 minutes
ConferenceTPMTech
- 02/23/2023
- Hilton Long Beach Convention Center
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism

30 Mar, 2018 | 07:41

Author Imran Khushal
Theme Healthcare & Pharmaceuticals

Minneapolis' DiaMedica Therapeutics Inc. raised additional gross proceeds of $2.5 million through a private placement of 10,534,059 units priced 24.5 cents each.

The biopharmaceutical company had previously raised $3.8 million and plans to use the $6.3 million to complete a mid-stage study of its drug DM199 to treat acute ischemic stroke.